Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isconova has taken over Danish research and development company Nordic Vaccine's assets for SEK 4,032,228 to ramp-up its patent position within vaccine systems and adjuvant technology.
Subscribe to our email newsletter
Nordic Vaccine commits to buying a new issue of Isconova shares to an amount of SEK 873,504 to a price of SEK 33.70 per share, corresponding to a dilution of 0.6 percent of the total number of outstanding shares in Isconova.
Nordic Vaccine’s product portfolio includes the Posintro-technology which is closely related to Isconovas Matrix-technology as well as a preclinical platform for needle free administration of vaccines through a dermal patch system.
Isconova CEO Lena Soderstrom said the acquisition of Nordic Vaccine is in line with Isconova’s strategy to take part in the ongoing market consolidation.
"With the acquired patents we will strengthen our commercial opportunities and patent family within iscom and Matrix-technologies," Soderstrom said.